Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGENUS INCAGEN · Entity 5774 | Chief Legal Officer and GC | June 20, 2018 | June 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGENUS INC
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options, right to buySEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2028-03-02 | Direct | 173,150 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 173,150 · Balance 173,150 F1: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, and vests over three years with one-third of the award vesting on March 2, 2019 and the balance vesting in equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, and vests over three years with one-third of the award vesting on March 2, 2019 and the balance vesting in equal quarterly installments thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 58,600 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 81,939 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-15 · Disposition to issuer · Disposed 22,425 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.06 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-15 · Disposition to issuer · Disposed 41,800 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2021 Filed Jul 19, 2021 17:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Disposition to issuerStock Options (Right to buy) · Derivative | 41,800 | Not disclosed Strike: $36.06 | Not disclosed |
DisclosureSEC source: 0001562180-21-004987 · primarydocument.xml · derivative · entry 4 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,800 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 17:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Disposition to issuerStock Option (right to buy) · Derivative | 22,425 | Not disclosed Strike: $8.76 | Not disclosed |
DisclosureSEC source: 0001562180-21-004987 · primarydocument.xml · derivative · entry 3 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,425 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 17:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Disposition to issuerStock Option (right to buy) · Derivative | 81,939 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001562180-21-004987 · primarydocument.xml · derivative · entry 2 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,939 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 17:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Disposition to issuerStock Option (Right to Buy) · Derivative | 58,600 | Not disclosed Strike: $35.50 | Not disclosed |
DisclosureSEC source: 0001562180-21-004987 · primarydocument.xml · derivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,600 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 16:52 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 58,600 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001562180-21-001263 · primarydocument.xml · derivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,600 Underlying: Common Stock · 58,600 shares Expires 2031-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2021, and the shares underlying the option vest in equal quarterly installments through February 16, 2025, subject to continued service. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 17:56 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,203 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-21-000392 · primarydocument.xml · derivative · entry 5 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,939 Underlying: Common Stock · 17,203 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 16, 2022. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 17:56 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 7,203 | $35.11 | $252,888.69 |
DisclosureSEC source: 0001562180-21-000392 · primarydocument.xml · nonDerivative · entry 4 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 17:56 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 1,227 | $33.69 | $41,342.05 |
DisclosureSEC source: 0001562180-21-000392 · primarydocument.xml · nonDerivative · entry 3 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,203 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.56 to $33.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 17:56 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 8,773 | $33.08 | $290,231.90 |
DisclosureSEC source: 0001562180-21-000392 · primarydocument.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,430 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.51 to $33.505. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 17:56 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 17,203 | $11.50 | $197,834.50 |
DisclosureSEC source: 0001562180-21-000392 · primarydocument.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:34 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 2,467 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001562180-20-003453 · primarydocument.xml · derivative · entry 8 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,425 Underlying: Common Stock · 2,467 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on March 7, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments through March 7, 2023. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:34 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,099 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-003453 · primarydocument.xml · derivative · entry 7 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,142 Underlying: Common Stock · 10,099 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 16, 2022. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:34 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 12,566 | $40.10 | $503,896.60 |
DisclosureSEC source: 0001562180-20-003453 · primarydocument.xml · nonDerivative · entry 5 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:34 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 2,467 | $8.76 | $21,610.92 |
DisclosureSEC source: 0001562180-20-003453 · primarydocument.xml · nonDerivative · entry 4 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:34 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 10,099 | $11.50 | $116,138.50 |
DisclosureSEC source: 0001562180-20-003453 · primarydocument.xml · nonDerivative · entry 3 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:34 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,744 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-003453 · primarydocument.xml · derivative · entry 6 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,241 Underlying: Common Stock · 4,744 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 16, 2022. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:34 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 4,744 | $40.01 | $189,817.40 |
DisclosureSEC source: 0001562180-20-003453 · primarydocument.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:34 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 4,744 | $11.50 | $54,556.00 |
DisclosureSEC source: 0001562180-20-003453 · primarydocument.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:03 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-003207 · primarydocument.xml · derivative · entry 3 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,985 Underlying: Common Stock · 400 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 16, 2022. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:03 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 400 | $40.13 | $16,052.00 |
DisclosureSEC source: 0001562180-20-003207 · primarydocument.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.03 to $40.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:03 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 400 | $11.50 | $4,600.00 |
DisclosureSEC source: 0001562180-20-003207 · primarydocument.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:17 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 789 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-003096 · primarydocument.xml · derivative · entry 3 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,385 Underlying: Common Stock · 789 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 16, 2022. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:17 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 789 | $33.65 | $26,550.09 |
DisclosureSEC source: 0001562180-20-003096 · primarydocument.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.13 to $35.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:17 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 789 | $11.50 | $9,073.50 |
DisclosureSEC source: 0001562180-20-003096 · primarydocument.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 17:52 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,300 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-003062 · primarydocument.xml · derivative · entry 7 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,174 Underlying: Common Stock · 2,300 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 16, 2022. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 17:52 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 2,300 | $35.19 | $80,939.30 |
DisclosureSEC source: 0001562180-20-003062 · primarydocument.xml · nonDerivative · entry 5 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 17:52 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 2,300 | $11.50 | $26,450.00 |
DisclosureSEC source: 0001562180-20-003062 · primarydocument.xml · nonDerivative · entry 4 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 17:52 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,998 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-003062 · primarydocument.xml · derivative · entry 6 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,474 Underlying: Common Stock · 2,998 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 16, 2022. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 17:52 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 1,043 | $34.09 | $35,552.01 |
DisclosureSEC source: 0001562180-20-003062 · primarydocument.xml · nonDerivative · entry 3 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.845 to $34.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 17:52 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 1,955 | $33.29 | $65,085.27 |
DisclosureSEC source: 0001562180-20-003062 · primarydocument.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.835 to $33.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 17:52 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 2,998 | $11.50 | $34,477.00 |
DisclosureSEC source: 0001562180-20-003062 · primarydocument.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:56 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 635 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001562180-20-002991 · primarydocument.xml · derivative · entry 3 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,892 Underlying: Common Stock · 635 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on March 7, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments through March 7, 2023. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:56 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 635 | $35.02 | $22,236.24 |
DisclosureSEC source: 0001562180-20-002991 · primarydocument.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:56 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 635 | $8.76 | $5,562.60 |
DisclosureSEC source: 0001562180-20-002991 · primarydocument.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 16:11 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 617 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001562180-20-002396 · primarydocument.xml · derivative · entry 5 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,527 Underlying: Common Stock · 617 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on March 7, 2019, and the shares underlying the option vest in equal quarterly installments through March 7, 2023, subject to continued service. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 16:11 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 130 | $32.92 | $4,279.05 |
DisclosureSEC source: 0001562180-20-002396 · primarydocument.xml · nonDerivative · entry 4 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $32.59 to $33.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 16:11 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 335 | $32.08 | $10,746.30 |
DisclosureSEC source: 0001562180-20-002396 · primarydocument.xml · nonDerivative · entry 3 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $31.57 to $32.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 16:11 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 152 | $31.17 | $4,737.90 |
DisclosureSEC source: 0001562180-20-002396 · primarydocument.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.57 to $31.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 16:11 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 617 | $8.76 | $5,404.92 |
DisclosureSEC source: 0001562180-20-002396 · primarydocument.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 16:53 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 41,800 | $0.00 Strike: $36.06 | $0.00 |
DisclosureSEC source: 0000899243-20-004897 · doc4.xml · derivative · entry 1 Valentine Karen · CIK 0001437152 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,800 Underlying: Common Stock · 41,800 shares Expires 2030-02-13 F1 · derivative.exercise_date: This option was granted on February 14, 2020, and the shares underlying the option vest in equal quarterly installments through February 14, 2024, subject to continued service. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,906 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001562180-20-001250 · primarydocument.xml · derivative · entry 8 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,144 Underlying: Common Stock · 1,906 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on March 7, 2019, and the shares underlying the option vest in equal quarterly installments through March 7, 2023, subject to continued service. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,567 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-001250 · primarydocument.xml · derivative · entry 7 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,472 Underlying: Common Stock · 2,567 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 19, 2018 and is scheduled to vest as to 25% of the shares underlying the option on July 16, 2019, with the remainder vesting in equal quarterly installments through July 16, 2022, subject to continued service. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 4,473 | $35.07 | $156,858.72 |
DisclosureSEC source: 0001562180-20-001250 · primarydocument.xml · nonDerivative · entry 5 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 2,567 | $11.50 | $29,520.50 |
DisclosureSEC source: 0001562180-20-001250 · primarydocument.xml · nonDerivative · entry 4 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 1,906 | $8.76 | $16,696.56 |
DisclosureSEC source: 0001562180-20-001250 · primarydocument.xml · nonDerivative · entry 3 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-001250 · primarydocument.xml · derivative · entry 6 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,039 Underlying: Common Stock · 1,500 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 19, 2018 and is scheduled to vest as to 25% of the shares underlying the option on July 16, 2019, with the remainder vesting in equal quarterly installments through July 16, 2022, subject to continued service. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 1,500 | $35.02 | $52,527.00 |
DisclosureSEC source: 0001562180-20-001250 · primarydocument.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 1,500 | $11.50 | $17,250.00 |
DisclosureSEC source: 0001562180-20-001250 · primarydocument.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,550 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-001122 · primarydocument.xml · derivative · entry 6 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,689 Underlying: Common Stock · 8,550 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 19, 2018 and is scheduled to vest as to 25% of the shares underlying the option on July 16, 2019, with the remainder vesting in equal quarterly installments through July 16, 2022, subject to continued service. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 8,550 | $35.03 | $299,506.50 |
DisclosureSEC source: 0001562180-20-001122 · primarydocument.xml · nonDerivative · entry 4 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.